Seeking Alpha Initiates Buy on ProQR Citing Axiomer Validation; DeepView Master Report Maintains WAIT

What happened

On August 21, 2026, Seeking Alpha published a bullish initiation on ProQR Therapeutics (PRQR) with a Buy rating, citing the 8-fold serum bile acid increase from AX-0810’s Phase 1 healthy-volunteer data and upcoming catalysts including full Phase 1 data by end-2026, pediatric biliary atresia data from China in H1 2027, and Phase 1 data for next-gen AX-0811 by end-2026. Our DeepValue master report, based on SEC filings and earlier public disclosures, had already incorporated these data points and maintained a WAIT rating, arguing that the market at $1.70 prices mechanism validation and Lilly support more aggressively than filing-backed patient progress. The article repeats the bull case but introduces no new evidence beyond what was previously disclosed, and it does not address the core uncertainties around patient efficacy, the small 10-patient China investigator-initiated trial, and heavy dilution from the June 2026 financing. Consequently, while the article may boost sentiment, it does not alter our fundamental assessment that the next 6–12 months are dominated by execution proof rather than efficacy. We continue to monitor the specific milestones outlined in the master report: AX-0810 Cohort 3 and follow-up data, AX-0811 clinical entry, and visible progress on the China IIT.

Implication

For investors, the Seeking Alpha Buy rating is a reminder that the bull thesis hinges on converting healthy-volunteer biomarker data into a credible patient-development path, a step that remains unproven. Our analysis shows that AX-0810’s 8-fold bile acid increase, while encouraging, may not translate to cholestatic disease patients, and the China IIT is a small open-label study with external controls that may not support registration without regulatory alignment. Additionally, the company’s June 2026 financing diluted shareholders by roughly 31%, and operating cash burn remains high at over €50 million annually, meaning another capital raise is likely unless catalysts materialize. The stock’s current valuation already reflects Lilly’s support and mechanistic validation, leaving limited upside without patient efficacy data. Therefore, we recommend waiting for clearer evidence of execution—such as sustained biomarker durability, AX-0811 human data, and actual China IIT enrollment—before considering a position.

Thesis delta

The thesis delta is neutral: the article reiterates known bullish points already captured in our master report, including the 8-fold biomarker target engagement and planned catalysts. It does not present new data or address the key risks of patient efficacy and financing dilution, which underpin our WAIT rating. As such, no shift in our investment thesis is warranted at this time.